Aeterna Zentaris Inc. | CIK:0001113423 | 3

  • Filed: 3/28/2018
  • Entity registrant name: Aeterna Zentaris Inc. (CIK: 0001113423)
  • Generator: Workiva (WebFilings)
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1113423/000162828018003635/0001628280-18-003635-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1113423/000162828018003635/aezs-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001113423
  • Open this page in separate window: Click

    • ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory

    Identifiable intangible assets with finite useful lives consist entirely of in-process R&D costs, patents and trademarks. Changes in the carrying value of the Company's identifiable intangible assets with finite useful lives are summarized below.
     
     
    Year ended December 31, 2017
     
    Year ended December 31, 2016
     
     
    Cost
     
    Accumulated amortization
     
    Carrying value
     
    Cost
     
    Accumulated amortization
     
    Carrying value
     
     
    $
     
    $
     
    $
     
    $
     
    $
     
    $
    Balances – Beginning of the year
     
    30,032

     
    (29,962
    )
     
    70

     
    31,151

     
    (30,914
    )
     
    237

    Additions
     
    —

     
    —

     
    —

     
    5

     
    —

     
    5

    Impairment (loss) reversal*
     
    —

     
    44

     
    44

     
    —

     
    (85
    )
     
    (85
    )
    Recurring amortization expense*
     
    —

     
    (38
    )
     
    (38
    )
     
    —

     
    (83
    )
     
    (83
    )
    Impact of foreign exchange rate changes
     
    4,214

     
    (4,200
    )
     
    14

     
    (1,124
    )
     
    1,120

     
    (4
    )
    Balances – End of the year
     
    34,246

     
    (34,156
    )
     
    90

     
    30,032

     
    (29,962
    )
     
    70

    _________________________
    * Recorded with R&D costs in the consolidated statements of comprehensive loss.